Trials / Completed
CompletedNCT01484561
A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis
A Phase 1, Randomized, Placebo-Controlled, Two-Period, Fixed Sequence Study To Evaluate The Effect Of CP-690,550 On Measured Glomerular Filtration Rate In Patients With Active Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 148 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of study is to explore the effect of CP-690,550 (Tofacitinib) on measures of kidney function in patients with active rheumatoid arthritis (RA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CP-690,550 or Placebo | CP-690,550 10 mg twice a day (BID) orally or placebo BID orally, approximately 72 days |
| DRUG | Placebo | Placebo BID orally, approximately 72 days |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2013-01-01
- Completion
- 2013-02-01
- First posted
- 2011-12-02
- Last updated
- 2014-04-02
- Results posted
- 2014-04-02
Locations
24 sites across 8 countries: United States, Czechia, Germany, Mexico, Poland, Russia, South Korea, Spain
Source: ClinicalTrials.gov record NCT01484561. Inclusion in this directory is not an endorsement.